CellCancer BiologyPeer-reviewed journal article
A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-induced Cell Death
Meredith Nicole Nix, Sai P. GourisankariD, Kevin BowmaniD, Sabin A. NettlesiD, H H Yang, Brendan G. DwyeriD, Roman C. SarottiD, Hind Z. AbuzaidiD, Michael M. Martinez, Nick A. PhillipsiD, Vincent Cabaud GibouiniD, Artur Hakobyan, Vahram ArakeloviD, Garik Petrosyan, Aram DavtyaniD, Yanlan Wang, Juste SimanauskaiteiD, Bryan A. RomeroiD, Hannah M. JonesiD, A. KrokhotiniD, Tara N. LowensohniD, Lei CheniD, Cara Low, Hannes S. VogeliD, Mark M. DavisiD, , Gerald R. CrabtreeiD
- Citations
- 17
- FWCI
- 24.57
- Field percentile
- top 1%
Abstract
Developing cancer therapies that induce robust death of the malignant cell is critical to prevent relapse. Highly effective strategies, such as immunotherapy, exemplify this observation. Here we provide the structural and molecular underpinnings for an approach that leverages chemical induced proximity to produce specific cell killing of diffuse large B cell lymphoma, the most common non-Hodgkins lymphoma. We develop KAT-TCIPs (lysine acetyltransferase transcriptional/epigenetic chemical inducers of proximity) that redirect p300 and CBP to activate programmed cell death genes normally repressed by the oncogenic driver, BCL6. Acute treatment rapidly reprograms the epigenome to initiate apoptosis and repress c-MYC. The crystal structure of the chemically induced p300-BCL6 complex reveals how chance interactions between the two proteins can be systematically exploited to produce the exquisite potency and selectivity of KAT-TCIPs. Thus, the malignant function of an oncogenic driver can be co-opted to activate robust cell death, with implications for precision epigenetic therapies.
- organism: human
- assay: ChIP-seq
- assay: proteomics
- research focus: cell type annotation
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rewiring Cancer Drivers to Activate Apoptosis
S. P. Gourisankar, A. Krokhotin, … G. R. Crabtree·NaturePeer-reviewed·Aug 10, 2023
- Borrowing Transcriptional Kinases to Activate Apoptosis
R. C. Sarott, S. P. Gourisankar, … N. Gray·bioRxiv·Oct 23, 2023
- MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugs.
Hai Vu Nguyen, Marcel Michla, … Suzanne Cory·bioRxiv·May 1, 2026
- Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma
Calixte Calaud, Emilio M. Serrano-López, … Pilar M. Domínguez·Blood NeoplasiaPeer-reviewed·Mar 2, 2026
- A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell Lymphoma
Ted B. Piorczynski, Yuxuan Liu, … Jennifer Effie Amengual·bioRxiv·Mar 13, 2025
- Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition
R. Winkler, A.-S. Mägdefrau, … C. Kosan·OncogenePeer-reviewed·Sep 6, 2022